The Diazyme Cholylglycine (CG) Assay is a dual vial liquid stable system, which provides reliable results. The assay has excellent sensitivity with a linear range up to 20 μg/mL. Diazyme's enzyme immunoassay method has excellent Within-Run precision CV% of 0.024%. The limit of detection of the Diazyme CG assay is 0.5 μg/mL. The Deming regression results showed a correlation of R2 of 0.9936, a slope of 0.9684, and a y-intercept of 0.0857.
Diazyme's CG assay is a homogenous enzyme immunoassay based on competition between cholylglycine in a sample and cholylglycine-G6PDH (Glucose-6-Phosphate Dehydrogenase) conjugate for specific antibody binding sites. Binding of the antibody to the analyte enzyme complex partially inhibits activity of the G6PDH. Cholylglycine presented in a sample binds to the anti-CG antibody and displaces enzyme cholylglycine conjugate resulting in increase of G6PDH activity, measured spectrophotometrically at 340 nm. The amount of cholylglycine presented in a sample is proportional to the increase of the absorbance at 340 nm. The instrument calculates the cholylglycine concentration of a patient specimen by interpolation of the obtained signal, relative to a 6-point calibration curve.
The Diazyme Cholylglycine (CG) assay is for the quantitative determination of Cholylglycine in human serum on automated clinical chemistry analyzers. Measurement of Cholylglycine is of use for the detection and evaluation of liver diseases and hepatic damage. For Research Use Only in USA.
|Available In Bulk Packaging Format Only